INFLUENCE OF THE DEFECTIVE METABOLISM OF SPARTEINE ON ITS PHARMACOKINETICS

被引：56

作者：

EICHELBAUM, M

SPANNBRUCKER, N

DENGLER, HJ

机构：

[1] Department of Medicine, University of Bonn, Bonn-Venusberg

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1979年 / 16卷 / 03期

关键词：

defective metabolism; pharmacogenetic defect; pharmacokinetics; renal excretion; sparteine;

D O I：

10.1007/BF00562060

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sparteine is metabolized by N1-oxidation, which in some subjects is defective. The defect has a pronounced effect on the kinetics of the drug. In non-metabolisers elimination of sparteine proceeds entirely via renal excretion by a capacity-limited process, 99,9% of the dose being excreted as unchanged drug. In metabolisers the drug is mainly eliminated by metabolic degradation. Pronounced differences in β-phase half-life and total plasma clearance were observed between metabolisers (156 min; 535 ml · min-1) and nonmetabolisers (409 min; 180 ml · min-1). © 1979 Springer-Verlag.

引用

页码：189 / 194

页数：6

共 9 条

[1]

BINNIG F, 1974, ARZNEIMITTEL-FORSCH, V24, P752

[2]

DENGLER H J, 1970, Pharmacologia Clinica, V2, P189, DOI 10.1007/BF00404298

[3] DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT [J].